Cargando…

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany

Background: About 400,000-500,000 people are infected with hepatitis C in Germany. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of first generation protease inhibitors has significantly improved the treatment of hepatitis C genotype 1 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stahmeyer, Jona T., Schauer, Svenja, Rossol, Siegbert, Heinrich Wedemeyer, Hans, Wirth, Daniel, Bianic, Florence, Krauth, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2013
Materias:	Nephrologic/Hepatologic Conditions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471398/ https://www.ncbi.nlm.nih.gov/pubmed/37662876

Ejemplares similares

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Economic study of the value of expanding HCV treatment capacity in Germany
por: Sbarigia, Urbano, et al.
Publicado: (2017)

High Costs of Dialysis Transportation in the United States: Exploring Approaches to a More Cost-effective Delivery System
por: Stephens, J. Mark, et al.
Publicado: (2013)

Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease
por: Blanchette, Christopher M., et al.
Publicado: (2014)

Cost-effectiveness of Chloride-liberal versus Chloriderestrictive Intravenous Fluids among Patients Hospitalized in the United States
por: Perrault, Louise, et al.
Publicado: (2016)

Outcomes, Healthcare Resource Utilization, and Costs of Overall, Community-Acquired, and Hospital-Acquired Acute Kidney Injury in COVID-19 Patients
por: Koyner, Jay L., et al.
Publicado: (2023)

System Dynamics Modeling Can be Leveraged to Predict Critical Care Pathways and Costs for End Stage Renal Disease: US Population to 2020
por: Fernandez, Luca, et al.
Publicado: (2015)

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
por: Krauth, Christian, et al.
Publicado: (2019)

A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
por: Kwon, Christina Soeun, et al.
Publicado: (2021)

Quality of Life in Wilson’s Disease: A Systematic Literature Review
por: Balijepalli, Chakrapani, et al.
Publicado: (2021)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)”
por: Krüger, Kathrin, et al.
Publicado: (2023)

Real‐world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)
por: Krüger, Kathrin, et al.
Publicado: (2022)

Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis
por: Bert, Florian, et al.
Publicado: (2016)

Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness
por: Bert, Florian, et al.
Publicado: (2021)

Assessing the Economic Burden and Benefit-cost of Treating Attention-deficit Hyperactivity Disorder in Germany
por: Kotsopoulos, Nikolaos, et al.
Publicado: (2013)

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study
por: Stahmeyer, Jona T., et al.
Publicado: (2016)

Resource Utilisation and Costs of Depressive Patients in Germany: Results from the Primary Care Monitoring for Depressive Patients Trial
por: Krauth, Christian, et al.
Publicado: (2014)

Comparison of tools for assessing the methodological quality of primary and secondary studies in health technology assessment reports in Germany
por: Dreier, Maren, et al.
Publicado: (2010)

Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection
por: Deuffic-Burban, S, et al.
Publicado: (2008)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models
por: Diedrich, Leonie, et al.
Publicado: (2023)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Triple Renal Arteries in a Cadaveric Kidney Donor: A Case Report
por: Damaskos, Christos, et al.
Publicado: (2020)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Telaprevir
Publicado: (2012)

The Cost of an Operating Room Minute for Heart Valve Procedures
por: Grossi, Eugene A., et al.
Publicado: (2015)

Impact of Out-of-pocket Costs on Varenicline Utilization and Persistence
por: Galaznik, Aaron, et al.
Publicado: (2014)

An Algorithm to Analyze Cost Heterogeneity using Counterfactual Scenarios in Endovascular versus Open Repair of Abdominal Aortic Aneurysm: Predicting Costs for Subsequent Patients
por: Jones, Christopher A., et al.
Publicado: (2014)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Transanal Irrigation for Managing Neurogenic Bowel Dysfunction in Japan
por: Sengoku, Atsushi, et al.
Publicado: (2018)

Explaining Obesity- and Smoking-related Healthcare Costs through Unconditional Quantile Regression
por: Borah, Bijan, et al.
Publicado: (2016)

Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis
por: Cullen, Katherine, et al.
Publicado: (2023)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Management of Chronic Kidney Disease in Morocco: A Cost-of-Illness Study
por: Chrifi Alaoui, Amina, et al.
Publicado: (2023)

Cost Analysis and Clinical Outcomes of Ambulatory Care Monitoring in Medicare Patients: Describing the Diagnostic Odyssey
por: Arnold, Renée JG, et al.
Publicado: (2015)

Cost of Serum Versus Skin Allergy Testing Among Medicare Fee-for-Service Beneficiaries in the United States
por: Kwong, Kenny Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u8hqrf7us92pa00hlnmdnice01